![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ARHGEF39 |
Gene summary for ARHGEF39 |
![]() |
Gene information | Species | Human | Gene symbol | ARHGEF39 | Gene ID | 84904 |
Gene name | Rho guanine nucleotide exchange factor 39 | |
Gene Alias | C9orf100 | |
Cytomap | 9p13.3 | |
Gene Type | protein-coding | GO ID | GO:0006928 | UniProtAcc | Q8N4T4 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
84904 | ARHGEF39 | HCC1_Meng | Human | Liver | HCC | 1.74e-19 | 4.29e-02 | 0.0246 |
84904 | ARHGEF39 | HCC1 | Human | Liver | HCC | 5.56e-14 | 2.54e+00 | 0.5336 |
84904 | ARHGEF39 | HCC2 | Human | Liver | HCC | 2.05e-18 | 1.17e+00 | 0.5341 |
84904 | ARHGEF39 | HCC5 | Human | Liver | HCC | 8.56e-18 | 1.12e+00 | 0.4932 |
84904 | ARHGEF39 | S014 | Human | Liver | HCC | 3.35e-02 | 2.47e-01 | 0.2254 |
84904 | ARHGEF39 | S015 | Human | Liver | HCC | 1.64e-02 | 2.45e-01 | 0.2375 |
84904 | ARHGEF39 | S016 | Human | Liver | HCC | 5.66e-07 | 3.44e-01 | 0.2243 |
84904 | ARHGEF39 | S028 | Human | Liver | HCC | 7.94e-05 | 3.05e-01 | 0.2503 |
84904 | ARHGEF39 | S029 | Human | Liver | HCC | 1.01e-04 | 2.88e-01 | 0.2581 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ARHGEF39 | SNV | Missense_Mutation | c.692A>T | p.Gln231Leu | p.Q231L | Q8N4T4 | protein_coding | deleterious(0.02) | possibly_damaging(0.526) | TCGA-G3-A25U-01 | Liver | liver hepatocellular carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
ARHGEF39 | SNV | Missense_Mutation | c.578N>A | p.Arg193Lys | p.R193K | Q8N4T4 | protein_coding | tolerated(0.72) | benign(0.01) | TCGA-97-7938-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
ARHGEF39 | SNV | Missense_Mutation | novel | c.144N>G | p.Phe48Leu | p.F48L | Q8N4T4 | protein_coding | deleterious(0) | probably_damaging(0.965) | TCGA-21-1077-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
ARHGEF39 | SNV | Missense_Mutation | c.712C>A | p.Pro238Thr | p.P238T | Q8N4T4 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-39-5031-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
ARHGEF39 | SNV | Missense_Mutation | novel | c.397N>A | p.Leu133Ile | p.L133I | Q8N4T4 | protein_coding | deleterious(0.05) | probably_damaging(0.999) | TCGA-56-8626-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
ARHGEF39 | SNV | Missense_Mutation | novel | c.147N>T | p.Leu49Phe | p.L49F | Q8N4T4 | protein_coding | tolerated(0.14) | possibly_damaging(0.506) | TCGA-CV-7247-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | III/IV | Unknown | Unknown | PD |
ARHGEF39 | SNV | Missense_Mutation | c.778N>A | p.Pro260Thr | p.P260T | Q8N4T4 | protein_coding | deleterious(0.02) | possibly_damaging(0.479) | TCGA-EJ-5524-01 | Prostate | prostate adenocarcinoma | Male | <65 | 9 | Unknown | Unknown | PD | |
ARHGEF39 | SNV | Missense_Mutation | c.907T>C | p.Ser303Pro | p.S303P | Q8N4T4 | protein_coding | deleterious(0.01) | benign(0.425) | TCGA-XK-AAIW-01 | Prostate | prostate adenocarcinoma | Male | >=65 | 9 | Unknown | Unknown | PD | |
ARHGEF39 | SNV | Missense_Mutation | c.949N>C | p.Glu317Gln | p.E317Q | Q8N4T4 | protein_coding | tolerated(0.15) | benign(0.025) | TCGA-BR-6565-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
ARHGEF39 | SNV | Missense_Mutation | novel | c.670N>A | p.Ser224Thr | p.S224T | Q8N4T4 | protein_coding | tolerated(0.11) | benign(0.001) | TCGA-D7-A6EY-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |